scholarly journals Association between metabolic syndrome, diabetes mellitus and prostate cancer risk

2013 ◽  
Vol 16 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Y R Lawrence ◽  
O Morag ◽  
M Benderly ◽  
V Boyko ◽  
I Novikov ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Cancer Risk ◽  
Prostate Cancer Risk

scholarly journals Diabetes Mellitus and Prostate Cancer Risk; A Nationwide Case–Control Study within PCBaSe Sweden

2013 ◽  
Vol 22 (6) ◽  
pp. 1102-1109 ◽  
Author(s):  
Katja Fall ◽  
Hans Garmo ◽  
Soffia Gudbjörnsdottir ◽  
Pär Stattin ◽  
Björn Zethelius
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Cancer Risk ◽  
Case Control Study ◽  
Prostate Cancer Risk ◽  
Case Control ◽  
Control Study

Diabetes mellitus and prostate cancer risk

The Prostate ◽  
2008 ◽  
Vol 68 (10) ◽  
pp. 1126-1132 ◽  
Author(s):  
Brandon L. Pierce ◽  
Stephen Plymate ◽  
Elaine A. Ostrander ◽  
Janet L. Stanford
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Cancer Risk ◽  
Prostate Cancer Risk

scholarly journals Metabolic syndrome and prostate cancer risk in a population-based case–control study in Montreal, Canada

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Audrey Blanc-Lapierre ◽  
Andrea Spence ◽  
Pierre I. Karakiewicz ◽  
Armen Aprikian ◽  
Fred Saad ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metabolic Syndrome ◽  
Cancer Risk ◽  
Case Control Study ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Case Control ◽  
Control Study

scholarly journals Diabetes Mellitus and Prostate Cancer Risk in Asian Countries: a Meta-analysis

2012 ◽  
Vol 13 (8) ◽  
pp. 4097-4100 ◽  
Author(s):  
Xiang-Ju Long ◽  
Shan Lin ◽  
Ya-Nan Sun ◽  
Zhen-Feng Zheng
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Asian Countries

scholarly journals Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank

2020 ◽  
Vol 148 (4) ◽  
pp. 825-834
Author(s):  
Maria J. Monroy‐Iglesias ◽  
Beth Russell ◽  
Danielle Crawley ◽  
Naomi E. Allen ◽  
Ruth C. Travis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metabolic Syndrome ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Uk Biobank ◽  
The Uk

Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 130-130
Author(s):  
Ausvydas Patasius ◽  
Marius Kincius ◽  
Donata Linkeviciute-Ulinskiene ◽  
Lina Zabuliene ◽  
Giedre Smailyte
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Cancer Risk ◽  
Cancer Registry ◽  
Lower Risk ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Diabetes Diagnosis ◽  
Prostate Cancers ◽  
Reduced Risk

130 Background: An inverse association has been shown between diabetes and prostate cancer risk. The aim of this study was to determine whether type 2 diabetes mellitus (T2DM) and metformin is associated with prostate cancer risk. Methods: A retrospective cohort design was used to examine the relationship between diabetes and prostate cancer risk. The cohort was composed of male patients identified with diagnosis of T2DM in the National Health Insurance Fund database during 2000–2016. Cancer cases were identified by record linkage with the Lithuanian Cancer Registry which is a nationwide population-based cancer registry that contains personal and demographic information, as well as information on diagnosis of all people diagnosed with cancer in Lithuania since 1978. We calculated standardized incidence ratios (SIRs) for prostate cancers as a ratio of observed number of cancer case in people with diabetes diagnosis to the expected number of cancer cases in the underlying general population. Results: Overall, 68,449 males were diagnosed with diabetes in Lithuania between 2000 and 2016 were included in final cohort. 2,754 prostate cancers were observed versus 3,111.26 expected within a period of observation entailing an SIR of 0.89 (95% CI: 0.85–0.92). Significantly lower risk of prostate cancer was found in diabetic patients in all age groups, there were no differences in prostate cancer risk by time since diabetes diagnosis. Significantly lower risk of prostate cancer also was found in both metformin users and never-users groups, with higher risk reduction in metformin users (SIR 0.71, 95% CI: 0.68–0.75) than in T2DM patients never-users (SIR 0.88, 95% CI: 0.80–0.96). Conclusions: In the large population-based study we found significantly decreased risk of prostate cancer among men with T2DM. Our study suggests that metformin use in patients with T2DM may be associated with reduced risk of developing prostate cancer.

scholarly journals Diabetes mellitus and prostate cancer risk

2010 ◽  
Vol 5 (6) ◽  
pp. 787-789
Author(s):  
Jeffrey K Mullins ◽  
Stacy Loeb
Keyword(s):  
Prostate Cancer ◽  
Diabetes Mellitus ◽  
Cancer Risk ◽  
Prostate Cancer Risk
Sign in / Sign up

Export Citation Format

Share Document